Colorectal Cancer

Translational analyses from NEOPRISM-CRC also link ctDNA clearance/kinetics and TCR clonality with pCRs, supporting biomarker-guided treatment selection.

Colton Jones, MD, and Joel Saltzman, MD, discuss the potential role of GLP-1 receptor agonists in CRC prevention based on retrospective data.

Experts highlight ctDNA-guided strategies, ADCs, and targeted therapies shaping CRC research in the first quarter of 2026.

Christopher Lieu, MD, discusses the need for global collaboration and interdisciplinary research to address the rise of early-onset CRC.

The FDA grants full approval to brexu-cel in mantle cell lymphoma, grants priority review to a lirafugratinib NDA in FGFR2+ pretreated cholangiocarcinoma, and more.

John L. Marshall, MD, discusses how the clinical reality of early-onset CRC in young, fit patients contradicts traditional lifestyle-based assumptions.

Research found that adjuvant immunotherapy plus chemotherapy in stage 3 colon cancer was associated with a reduction in recurrence vs chemotherapy alone.

Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.

We recap the top regulatory decisions of March in GI malignancies.

The top 5 OncLive TV videos of the week cover insights in bladder cancer, colorectal cancer, breast cancer, chronic myeloid leukemia, and multiple myeloma.

During CRC Awareness Month, John L. Marshall, MD discusses whether the biology and origin of EO-CRC fundamentally differ from that of late-onset disease.

The top 5 OncLive TV videos of the week cover insights in colorectal cancer, breast cancer, bladder cancer, and more

Shubham Pant, MD, MBBS, discusses data from the phase 3 BREAKWATER trial supporting upfront targeted therapy in BRAF V600E–mutant mCRC.

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study evaluating the MET-directed ADC Temab-A vs SOC active surveillance in postadjuvant, ctDNA-positive CRC.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.

Shubham Pant, MD, MBBS, discusses the importance of early biomarker testing in mCRC to guide targeted therapy selection and ensure full clinical benefit.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

February brought key GI cancer updates: FDA approvals in BRAF+ mCRC and pancreatic cancer, plus new fast track and orphan designations.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Encorafenib plus cetuximab and fluorouracil-based chemotherapy has received traditional FDA approval for BRAF V600E–mutant metastatic colorectal cancer.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Topline data from cohort 3 of BREAKWATER showed improvements in key secondary end points of PFS and OS in previously treated, BRAF V600E–mutant mCRC.

Christopher Lieu, MD, expands on current treatment strategies and factors informing third-line sequencing decisions in mCRC.